Evolent Health, Inc. (EVH) 股票分析

公司概述

Evolent Health, Inc. operates primarily through its subsidiary to deliver specialty care management services across the oncology, cardiology, and musculoskeletal sectors within the United States, while simultaneously providing an integrated value-based care platform for health plan administration and management. The company functions within the Healthcare sector, specifically the Health Information Services industry, positioning it as a provider of critical administrative and operational support to the broader healthcare ecosystem. As of the latest data, Evolent Health, Inc. holds a market capitalization of $272.40M and generates annual revenue of $1.88B, employing a workforce of 4200 individuals to execute its operational strategy. These financial figures indicate a mid-to-large scale enterprise within the specialized health services niche, where the substantial revenue base suggests significant operational reach despite the relatively modest market valuation relative to its income generation capacity.

财务健康

Evolent Health, Inc. reported a trailing twelve-month revenue of $1.88B, yet it recorded a net income of -$579,401,024, creating a substantial gap between top-line revenue and bottom-line profit that highlights a highly leveraged cost structure and significant operating expenses. Despite the negative net income, the company maintains an EBITDA of $88.22M, which serves as a crucial metric for assessing its operational profitability before interest and tax impacts. The company demonstrates a free cash flow of $98.41M, indicating that its core operations generate sufficient cash to cover capital expenditures and potentially fund strategic initiatives or debt servicing without relying on external financing. Margin analysis reveals a gross margin of 21.3%, an operating margin of -2.1%, and a profit margin of -28.5%, suggesting that while the company retains a portion of revenue after direct costs, high overheads and interest obligations are eroding operating and net profits significantly. On the balance sheet, Evolent Health holds $151.86M in cash against total debt of $989.70M, resulting in a debt-to-equity ratio of 238.37, which characterizes the balance sheet as highly leveraged and sensitive to interest rate fluctuations. The current ratio stands at 1.31, indicating that the company possesses adequate short-term assets to cover its immediate liabilities, though the margin is relatively tight given the high debt load. Furthermore, the return on equity is -66.5% and the return on assets is -0.1%, metrics that reveal that current management effectiveness is currently constrained by the company's significant losses and high capitalization, preventing positive returns on the shareholders' invested capital.

估值评估

The valuation metrics for Evolent Health, Inc. show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at 5.52, implying that the market prices the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio is 0.66, indicating that the stock trades at a significant discount to its book value, which may reflect market skepticism regarding the company's ability to generate sustainable earnings or the high cost of its capital structure. Alternative valuation measures include a price-to-sales ratio of 0.15 and an EV/EBITDA of 12.59, suggesting that the market values the company's revenue and adjusted earnings conservatively compared to industry peers with positive earnings. The stock has experienced extreme volatility, with a 52-week high of $12.06 and a 52-week low of $2.10, meaning the current trading price sits within a wide range that reflects uncertainty about the path to profitability. The beta value of 0.37 indicates that the stock exhibits low price volatility relative to the broader market, moving less than half as much as the general equity market in response to standard market movements.

Growth & Income

Evolent Health, Inc. is currently experiencing a revenue contraction with a year-over-year revenue growth rate of -27.5%, while the earnings growth rate is N/A due to the reported net loss, preventing a direct comparison of earnings expansion versus revenue decline. The absence of a dividend yield (N/A) and a payout ratio of 0.0% signifies that the company is not distributing cash to shareholders, as the negative net income renders any dividend payment unsustainable. Consequently, the company's strategy focuses on reinvesting limited free cash flow and maintaining operations to potentially restore profitability rather than generating income through dividends. The overall growth and income profile is characterized by a significant decline in revenue and a complete absence of dividend income, reflecting a company in a challenging transition phase where capital preservation takes precedence over growth or shareholder returns.